Experts are asking whether the study and treatment of myeloproliferative neoplasms (MPNs) is ready for a new era with new end ...

NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative ...

There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, ...

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx ...

Lung cancer (LC) continues to represent the second most common neoplasm in both sexes and the leading cause of cancer-related mortality, with approximately 1.8 million deaths in 2022. 70% of patients ...

Discover important insights into the clonal evolution of blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive ...

Remember, it's the central part of your body and pumps that blood through you. Have to take care of it. I know you're looking ...

IN 1848 Bence Jones reported his unique findings in the urine of a grocer who had a malignant disease involving the bones, afterwards identified as multiple myeloma 1. Bence Jones described a ...

Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which the bone marrow produces an excess combination of white blood cells, red blood cells, and platelets. This ...

About The Study: Decades following treatment, one-third of childhood cancer survivors in this study reported elevated fear their cancer will recur or a subsequent malignant neoplasm will develop.

Overall, the preoperative factors of surgical indication, T stage, nodal status, M stage, biopsy result, neoplasm and neoplasm type, and multifocality were significantly associated with an ...